NFKB1 and metabolic disease: Fifth, conduct drug development and clinical trials based on the SIRT1-ER stress-NF-κB pathway to promote its application in the prevention and treatment of metabolic diseases, cardiovascular and cerebrovascular diseases, neurodegenerative diseases, and inflammatory diseases.